Literature DB >> 15247721

Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.

Terrence H Diamond1, Joseph Bucci, John H Kersley, Peter Aslan, William B Lynch, Carl Bryant.   

Abstract

PURPOSE: We determined the risk factors for osteoporosis and spinal fractures in men with prostate cancer receiving androgen deprivation therapy.
MATERIALS AND METHODS: We performed a retrospective analysis of 87 consecutive men with prostate cancer receiving androgen deprivation therapy referred for evaluation of osteoporosis. Data were comprised of lateral thoracolumbar radiographs, bone densitometry, serum biochemistry and a detailed assessment of osteoporotic risk factors. Multivariate regression analysis was used to determine the major risk factors for osteoporosis and spinal fractures.
RESULTS: There were 38 (44%) men who were 74.5 years old with radiographic evidence of spinal fractures. They had an initial mean prostate specific antigen of 52.8 ng/ml and had received androgen deprivation therapy for a mean of 39.6 months (95% confidence interval 28.7 to 50.4). Mean spinal (quantitative computerized tomography t-score -4.2) and femoral neck bone mineral densities (dual energy x-ray absorptiometry t-score -2.1) were significantly lower than in men without spinal fractures (p < 0.001 for all measurements). In the regression analysis the duration of androgen deprivation therapy (p = 0.002), serum 25-hydroxyvitamin D levels (p = 0.003) and a history of alcohol excess (defined as more than 4 standard drinks daily, p = 0.04) were the main determinants of spinal fractures.
CONCLUSIONS: Prolonged androgen deprivation therapy, low serum 25-hydroxyvitamin D levels and a history of alcohol excess are important risk factors for osteoporosis and spinal fractures in men with prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247721     DOI: 10.1097/01.ju.0000130508.61020.66

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

Review 1.  A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants.

Authors:  Lene Thorsen; Kerry S Courneya; Clare Stevinson; Sophie D Fosså
Journal:  Support Care Cancer       Date:  2008-02-15       Impact factor: 3.603

2.  Vertebral fractures and the misclassification of osteoporosis in men with prostate cancer.

Authors:  Sarah Sullivan; Julie Wagner; Neil M Resnick; Joel Nelson; Subashan K Perera; Susan L Greenspan
Journal:  J Clin Densitom       Date:  2011-07-01       Impact factor: 2.617

3.  The Effect of Bisphosphonates on Bone Mineral Density in Metastatic Prostate Cancer Patients Who Are Treated with Anti-Androgen Drugs and Radiotherapy.

Authors:  Ayhan Karaköse; Mehmet B Yüksel; Özgü Aydoğdu; Bilal Gümüş; Yusuf Z Ateşçi; Zafer Akan
Journal:  Curr Urol       Date:  2014-08-20

Review 4.  A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma.

Authors:  Ary Serpa Neto; Marcos Tobias-Machado; Marcos A P Esteves; Marília D Senra; Marcelo L Wroclawski; Fernando L A Fonseca; Rodolfo B dos Reis; Antônio C L Pompeo; Auro Del Giglio
Journal:  BMC Urol       Date:  2010-05-19       Impact factor: 2.264

Review 5.  Cancer-associated bone disease.

Authors:  R Rizzoli; J-J Body; M-L Brandi; J Cannata-Andia; D Chappard; A El Maghraoui; C C Glüer; D Kendler; N Napoli; A Papaioannou; D D Pierroz; M Rahme; C H Van Poznak; T J de Villiers; G El Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2013-10-22       Impact factor: 4.507

6.  Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy.

Authors:  Maria E Suarez-Almazor; Prashanth Peddi; Ruili Luo; Hoang T Nguyen; Linda S Elting
Journal:  Support Care Cancer       Date:  2013-10-22       Impact factor: 3.603

7.  SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study.

Authors:  Pilar Ma Samper Ots; Julia Luisa Muñoz García; Yesika Ríos Kavadoy; Ma Luz Couselo Paniagua; Elena Villafranca Iturre; Milagrosa Rodríguez Liñán; Ana María Pérez Casas; Rodrigo Muelas Soria; Blanca Ludeña Martínez; José López Torrecilla; Manuel Casaña Giner; Almudena Zapatero Laborda; Ma Magdalena Márquez García-Salazar
Journal:  Rep Pract Oncol Radiother       Date:  2015-09-29

8.  Protective effect of carboxymethyl-glucan (CM-G) against DNA damage in patients with advanced prostate cancer.

Authors:  Marciane Magnani; Raul Jorge Hernan Castro-Gomez; Mateus Prates Mori; Hellen Kuasne; Emerson Pereira Gregório; Farid Libos; Ilce Mara de Syllos Cólus
Journal:  Genet Mol Biol       Date:  2011-03-01       Impact factor: 1.771

9.  Exercise behavior in cancer survivors and associated factors.

Authors:  Gunhild Maria Gjerset; Sophie Dorothea Fosså; Kerry S Courneya; Eva Skovlund; Lene Thorsen
Journal:  J Cancer Surviv       Date:  2010-10-02       Impact factor: 4.442

10.  Bone densitometric assessment and management of fracture risk in Indian men of prostate cancer on androgen deprivation therapy: Does practice pattern match the guidelines?

Authors:  Manas R Pradhan; Anil Mandhani; Saurabh S Chipde; Alok Srivastava; Manmeet Singh; Rakesh Kapoor
Journal:  Indian J Urol       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.